Skip to main content
. 2021 Jun 25;9(7):731. doi: 10.3390/biomedicines9070731

Table 3.

Number of responders to thalamic DBS during follow-up (VAS average pain scores).

FU I FU II FU III FU IV
≥50% ≥30% ≥50% ≥30% ≥50% ≥30% ≥50% ≥30%
All available patients 17/33 21/33 15/30 20/30 13/25 17/25 10/18 16/18
Facial pain 3/5 3/5 4/5 4/5 3/5 3/5 2/5 4/5
CRPS 4/7 5/7 3/7 3/7 2/5 2/5 2/3 3/3
Poststroke/central(except thalamus) 4/7 6/7 3/7 6/7 2/6 5/6 2/4 4/4
Spinal cord lesion 1/3 1/3 1/2 1/2 1/1 1/1 0/1 0/1
Brachial plexus injury 2/3 2/3 2/3 2/3 2/3 3/3 3/3 3/3
Postherpetic pain 3/3 3/3 2/2 2/2 2/2 2/2 1/1 1/1
Central thalamic 0/1 1/1 0/0 0/0 0/0 0/0 0/0 0/0
Other 0/4 0/4 0/4 2/4 1/3 1/3 0/1 1/1
FBSS 0/2 0/2 0/2 1/2 1/1 1/1 0/0 0/0
Peripheral nerve 0/1 0/1 0/1 1/1 0/1 0/1 0/1 1/1
Phantom limb 0/1 0/1 0/1 0/1 0/1 0/1 0/0 0/0

The number of responders defined by improvement of the VAS average pain score by ≥50% and by ≥30% is shown in relation to the total number of patients for whom follow-up was available in the corresponding follow-up period.